Cargando…
Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
Though anti-vascular endothelial growth factor therapy has become the standard treatment for exudative age-related macular degeneration (AMD), retreatment after the initial loading injection is inevitable in most eyes with residual or recurrent exudative changes. In the present study, we studied 140...
Autores principales: | Kikushima, Wataru, Sakurada, Yoichi, Yoneyama, Seigo, Sugiyama, Atsushi, Tanabe, Naohiko, Kume, Atsuki, Mabuchi, Fumihiko, Iijima, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339812/ https://www.ncbi.nlm.nih.gov/pubmed/28266609 http://dx.doi.org/10.1038/srep44020 |
Ejemplares similares
-
Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration
por: Sakurada, Yoichi, et al.
Publicado: (2016) -
Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration
por: Fukuda, Yoshiko, et al.
Publicado: (2019) -
Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
por: Shijo, Taiyo, et al.
Publicado: (2020) -
Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Yoneyama, Seigo, et al.
Publicado: (2020) -
Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)